Koers Cytori Therapeutics Inc Nasdaq
Aandelen
US23283K2042
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 6,93 mln. 6,39 mln. | Omzet 2025 * | 2,87 mln. 2,64 mln. | Marktkapitalisatie | 16,73 mln. 15,43 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -17 mln. -15,68 mln. | Nettowinst (verlies) 2025 * | -31 mln. -28,59 mln. | EV/omzet 2024 * | 2,42 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 5,84 x |
K/w-verhouding 2024 * |
-0,97
x | K/w-verhouding 2025 * |
-0,78
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 93,82% |
Recentste transcriptie over Cytori Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 61 | 01-10-02 |
Andrew Sims
DFI | Director of Finance/CFO | 51 | 06-02-20 |
Pius Maliakal
CTO | Chief Tech/Sci/R&D Officer | - | 27-07-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 61 | 01-10-02 |
Richard Hawkins
CHM | Chairman | 75 | 01-12-07 |
Robert Lenk
BRD | Director/Board Member | 75 | 01-03-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+59,34% | 55,07 mld. | |
-1,50% | 41,79 mld. | |
+44,36% | 40,22 mld. | |
-8,29% | 28,17 mld. | |
+12,09% | 26,28 mld. | |
-21,07% | 18,93 mld. | |
+6,84% | 13,03 mld. | |
+28,50% | 12,26 mld. | |
+26,47% | 12,21 mld. |